Fulgent Genetics reports Q2 EPS 7c, consensus (18c)

Reports Q2 revenue $81.8M, consensus $76.21M. Ming Hsieh, chairperson of the board of directors and CEO, said, “In the first half of the year, we made good progress in growing revenue for our Laboratory Services business and in advancing our clinical trials for the Therapeutic Development business. I am pleased with the second quarter results and look forward to continued progress in the balance of 2025.”